menu
    • menu

    Company profile for Galimedix Therapeutics

    NEW Drugs in Dev: 2
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Galimedix Therapeutics is a Phase 2 neuropharmaceutical company developing novel first-in-class drugs with ground-breaking potential to slow or stop the progression of neurodegeneration and to improve function in glaucoma and dry AMD – leading causes of blindness – and also in Alzheimer’s disease. Based in the United States, Galimedix is a Phase 2 clinical stage pharmaceutical and ophthalmic company developing transform...
    Galimedix Therapeutics is a Phase 2 neuropharmaceutical company developing novel first-in-class drugs with ground-breaking potential to slow or stop the progression of neurodegeneration and to improve function in glaucoma and dry AMD – leading causes of blindness – and also in Alzheimer’s disease. Based in the United States, Galimedix is a Phase 2 clinical stage pharmaceutical and ophthalmic company developing transformative treatments based on a novel mechanism of action directed to the common cause for several neurodegenerative diseases: toxic oligomers of amyloid beta (Aβ).

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Galimedix TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    3704 Calvend Lane Kensington, MD 20895
    Telephone
    Telephone
    +972-4-9905139
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.galimedix.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Clinical Outsourcing

    Clinical Outsourcing

    Not Confirmed

    envelop Contact Supplier

    Clinical Outsourcing

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Galimedix Therapeutics Unveils Strong Phase 1 Results
    Galimedix Therapeutics Unveils Strong Phase 1 Results

    04 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/04/3200252/0/en/Galimedix-Therapeutics-presents-compelling-Phase-1-study-results-showing-excellent-safety-and-pharmacokinetics-with-oral-small-molecule-GAL-101-at-CTAD-2025.html

    GLOBENEWSWIRE
    04 Dec 2025
    Share Share
    Galimedix Completes Phase 1 Study for Alzheimer’s with GAL-101
    Galimedix Completes Phase 1 Study for Alzheimer’s with GAL-101

    12 Sep 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/09/12/3149131/0/en/Progress-in-clinical-development-for-Alzheimer-s-and-other-indications-Galimedix-Therapeutics-successfully-completes-Phase-1-study-with-oral-small-molecule-GAL-101-an-amyloid-beta-.html

    GLOBENEWSWIRE
    12 Sep 2025
    Share Share
    Galimedix's Alzheimer's Oral Candidate Passes Phase 1 Safety Test
    Galimedix's Alzheimer's Oral Candidate Passes Phase 1 Safety Test

    12 Sep 2025

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/galimedix-seeks-phase-2-funding-after-oral-alzheimers-candidate-clears-safety-test

    FIERCE BIOTECH
    12 Sep 2025
    Share Share
    Galimedix Therapeutics publishes new data on GAL-201 in Alzheimer
    Galimedix Therapeutics publishes new data on GAL-201 in Alzheimer

    21 May 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/05/21/3085672/0/en/Galimedix-Therapeutics-publishes-new-data-in-peer-reviewed-International-Journal-of-Molecular-Sciences-demonstrating-disease-modifying-capability-of-GAL-201-in-Alzheimer-s-disease.html

    GLOBENEWSWIRE
    21 May 2025
    Share Share
    Galimedix Completes Ph 1 SAD Trial Of GAL-101
    Galimedix Completes Ph 1 SAD Trial Of GAL-101

    06 May 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/05/06/3075003/0/en/Galimedix-Therapeutics-completes-single-ascending-dose-part-of-Phase-1-study-with-oral-small-molecule-GAL-101-an-amyloid-beta-aggregation-modulator.html

    GLOBENEWSWIRE
    06 May 2025
    Share Share
    Galimedix Therapeutics Initiates Phase 2 Study for GAL-101
    Galimedix Therapeutics Initiates Phase 2 Study for GAL-101

    23 Dec 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/12/23/3001385/0/en/Galimedix-Therapeutics-initiates-pivotal-Phase-2-study-with-GAL-101-eye-drops-in-dry-AMD.html

    GLOBENEWSWIRE
    23 Dec 2024
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search